Amoxil is a powerful antibacterial drug! The appearance of amoxicillin protected by clavulanic acid on the market is difficult to overestimate. After all, antibiotics are one of the main classes of medicines, without which modern medicine is simply unthinkable. At the same time, despite the fact that the nomenclature of this class of drugs today includes a very wide range, humanity will always need new antibacterial drugs. The reason for this is the ability of microorganisms to develop resistance (resistance) antibiotics.
One of the most specific mechanisms of protection in microorganisms is the inactivation of antimicrobial agents by enzymes-beta-lactamases, which are able to destroy penicillins and cephalosporins. Such a defense mechanism is used by Staphylococcus aureus, Hemophilus influenzae, Moraxella (Moraxella catarrhalis), Escherichia coli, Klebsiella pneumoniae, Gram-negative Bacillus Bacteroides fragilis. These are the main pathogens of infectious and inflammatory diseases of various organs and systems.
Alas, the ability of microbes to resist progresses. So, back in 1956, Lawrence Garrod and Pamela Waterworth in the article “Antibiotics versus Staphylococci” noted that one of the most important problems of modern medical practice in hospitals is the widespread prevalence of staphylococcal infections resistant to antibiotics. However, even after half a century in this regard, little has changed: the resistance of microorganisms to antibiotics continues to be the scourge of antibiotic therapy. The researchers draw a disappointing conclusion: the formation of a number of resistant strains of pathogenic bacteria is inevitable. At the same time, some of them were determined to be resistant to all classes of antimicrobial agents. It is obvious that this not only negates all the efforts of the developers of antibacterial drugs, but also puts humanity in serious danger of becoming, in the end, virtually defenseless against bacterial infection.
In order to overcome resistance, researchers in the course of a long study have obtained compounds that can inactivate the beta-lactamase enzymes, which are so named because of their ability to destroy the beta-lactam ring of this class of drugs. One of these inhibitors — clavulanic acid — was synthesized in the early 1970s. This compound has a β-lactam structure similar to that of penicillins, which allows it to bind to the penicillin-binding proteins of Gram-positive and gram-negative bacteria and promote lysis of the bacterial wall. Due to this, clavulanic acid exhibits activity relative to clinically important plasmid β-lactamases, which are often responsible for the occurrence of cross-resistance to antibiotics. In addition, this property of clavulanate allows it to also exhibit its own antibacterial activity.
By combining clavulanic acid with an antibiotic such as amoxicillin, a fundamentally new drug with a set of special effects was obtained. By irreversibly blocking beta-lactamases, clavulanic acid opens the way for amoxicillin to attack, allowing it to exhibit its full set of properties: a wide range of antibacterial activity; high bioavailability even with oral administration (it is not destroyed by gastric acid, food consumption does not affect the absorption of the drug); and, as a result, the ability to create high concentrations of the active substance in the tissues and biological fluids of the body, allowing you to effectively fight microorganisms.
Few people know that thanks to the amoxicillin+clavulanic acid complex, it is possible not only to enhance the antibacterial effect of the antibiotic, but also to increase the intracellular bactericidal activity of human leukocytes. This activity of antimicrobial immunity increases both against bacterial strains that produce and do not produce b-lactamase (Finlay J., Miller L., Poupard J. A., 2003).
All these properties of the amoxicillin+clavulanate complex allow the drug AMOXIL-K to show high clinical efficacy in many infections of various organs and systems, which does not change over time.
The scope of application of the drug AMOXIL-K is surprising in its breadth, since it shows a high ability to bactericidally affect both Gram-positive and gram-negative aerobic and anaerobic flora. Therefore, this drug can be taken as a monotherapy even in cases where therapy with a combination of two or more antibiotics would be needed. Thanks to this, the doctor, on the one hand, has the opportunity to influence the frequency of adverse reactions, and on the other, does not give microorganisms a chance to develop resistant strains. In addition, ASMOXIL-K allows you to implement one of the most important tasks of antibiotic therapy — to destroy the bacteria in the focus of infection, that is, to achieve their complete eradication: only this guarantees the absence of relapse or chronization of the disease.
Amoxil is a powerful antibacterial drug and is recommended for
- upper and lower respiratory tract infections (tonsillitis, sinusitis, otitis media, exacerbation of chronic bronchitis, pneumonia),
- infections of the genitourinary system (cystitis, urethritis, pyelonephritis, sexually transmitted infections, gynecological and obstetric infections);
- infectious lesions of the skin and soft tissues, bones and joints (osteomyelitis);
- for the purpose of perioperative prevention of surgical infection.
At the same time, along with a wide spectrum of action and high efficiency, which (as shown by the long experience of using the amoxicillin+clavulanic acid complex) persists for a long time, amoxil also has a favorable safety profile, as well as good tolerability. The latter circumstance allows the use of AMOXIL in children; patients with concomitant pathology; elderly patients who, as a rule, have age-related disorders of the liver and kidneys.
It is obvious that thanks to the appearance of the drug amoxil for parenteral and oral administration, which can only be called a good antibiotic, the treatment of various infections has become even more accessible to patients, and our care for them and the opportunity to help them is even closer.